ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Wireless, Deep-Seeing Smart Pill: A NIR-II Fluorescence Imaging Capsule Endoscope for Gastrointestinal Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Gastrointestinal cancer detection technologies are evolving; capsule endoscopy (CE) overcomes the invasiveness of tethered endoscopes. However, current CEs exhibit limited penetration depth and low SNR due to strong photon scattering, absorption, and autofluorescence in biological tissues, potentially resulting in missed deep or small lesions. This study reports a near-infrared-II fluorescent imaging capsule endoscope (NIR-II FICE), a "smart pill" designed for early gastrointestinal cancer diagnosis. NIR-II FICE can detect NIR-II-specific fluorescence signals above 900 nm from lesional tissues using the NIR-II fluorescent nanoprobe (FNP). It possesses the advantages of high sensitivity, high resolution, strong tissue penetration ability, high SNR, and high-contrast imaging. Experiments show NIR‑II FICE can detect FNP at concentrations as low as 5 µg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.